Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 159 participants.

Also called NCT07820111

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 159 participants (enrolled count) (from the registry)
Sponsor
Zagazig University (from the registry)
Registry
  • NCT NCT07820111
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Saudi Arabia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07820111. Randomized; no masking; primary purpose treatment. Start 2025-10-18 (actual); primary completion 2026-03-17 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial
Condition
Obese Diabetics
Condition
Obese Non Diabetic
Intervention (Drug)
Dulaglutide 1.5 MG/ML
Intervention (Drug)
Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution
Intervention (Drug)
Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician
Intervention (Drug)
Dulaglutide 0.75mg subcutaneous injection
Intervention (Drug)
Semaglutide 1.0 mg
Intervention (Drug)
Tirzepatide (Flexible titration)
Lead sponsor
Zagazig University (class: other government)

Record details

Record id
cardio:ct-nct07820111
Content hash
5b661f50400364b854c58131abb023f3f487805a9d8ea2440f0e16779f83e40c